A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CBC / contralateral breast cancer

[Related PubMed/MEDLINE]
Total Number of Papers: 182
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CBC  (>> Co-occurring Abbreviation)
Long Form:   contralateral breast cancer
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study. CI, RR, RT, WECARE
2020 Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. PRS313, PRSs, SD
2020 Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy. CPM
2020 Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. HR
2020 Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. BCT, BLM, HR, SEER, ULM
2020 Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation. ---
2020 Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. BC, ER, GPER, GPR30, PR
2020 Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. AUC, BC, CI, E/O
2020 Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer. RT
10  2020 The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis. ---
11  2020 The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study. CIs, HRs
12  2019 Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. HER2, HR
13  2019 Are mammographic density phenotypes associated with breast cancer treatment response and clinical outcomes? A systematic review and meta-analysis. BC, BMD, MD, MDR, QUIPS
14  2019 Comparative Analysis of Outcomes and Clinicopathological Characteristics of Synchronous and Metachronous Contralateral Breast Cancer: A Study of the SEER Database. BCSS, ER, IDC, MCBC, PR, sCBC
15  2019 Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer. CI, HBOC, HR, IBTR
16  2019 Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal. DM, IBTR, REC
17  2019 Expression of HIF-1alpha is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. EGFR, ER, HIFs
18  2019 Long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ. BCS, DCIS, LR, RT
19  2019 National trends of synchronous bilateral breast cancer incidence in the United States. mBBC, SBBC, SEER
20  2019 Nonaspirin NSAIDs and contralateral breast cancer risk. CIs, COX, HRs, NSAIDs
21  2019 Personalizing Decision-Making for Patients Choosing Contralateral Prophylactic Mastectomy: A Utility Analysis of Genetic Factors and the Relative Risk of Breast Cancer. CPM
22  2019 Physician Knowledge of Breast Cancer Recurrence and Contralateral Breast Cancer Risk is Associated with Increased Recommendations for Contralateral Prophylactic Mastectomy: a Survey of Physicians at NAPBC-Accredited Centers. CPM, ER, LR, OR
23  2019 Polygon method: A systematic margin assessment for breast conservation. BCS, DCIS, IBTR, IDC, RT
24  2019 Prediction and clinical utility of a contralateral breast cancer risk model. AUC, PI
25  2019 Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. ER
26  2019 Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. BMI, PBC
27  2019 Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. BCS, DCIS, IBTR, LCIS
28  2019 The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. BC, CI, ER, HRs
29  2019 What does risk of future cancer mean to breast cancer patients? ---
30  2018 Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. CPM
31  2018 Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. ARs, RRs, UBC, WECARE
32  2018 CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. AS, CIs, RRs
33  2018 Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy. BC, CPM, DA, IPDAS
34  2018 Estrogen-receptor status and risk of contralateral breast cancer following DCIS. DCIS, ER
35  2018 Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. AI, DFS, OS, RCTs, RFS
36  2018 Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. IBTR
37  2018 Low Lifetime Risk of Contralateral Breast Cancer in a Middle-Income Asian Country: Evidence to Guide Post-treatment Surveillance. CRRM
38  2018 Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. CIs, HRs
39  2018 Mortality after contralateral breast cancer in Denmark. CIs, HRs, UBC
40  2018 Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data. BC, PS
41  2018 Predictive value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer? BMRI, ER, PR
42  2018 Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. AJCC, IBTR
43  2018 Statin use and risk of contralateral breast cancer: a nationwide cohort study. CIs, HRs
44  2018 The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. CI, MD, OR, UBC
45  2018 Validation of a personalized risk prediction model for contralateral breast cancer. CPM, JH, MDA
46  2017 Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. CI, RR, UBC
47  2017 Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. AIs, RR
48  2017 Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. CI, PRS, SNP, UBC, WECARE
49  2017 ATM, radiation, and the risk of second primary breast cancer. AT, ATM
50  2017 Bilateral Mastectomy as Overtreatment for Breast Cancer in Women Age Forty Years and Younger with Unilateral Operable Invasive Breast Cancer. BC, BCS, BM, DFS, UM
51  2017 Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. CI
52  2017 Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? BCS, CRR, DCIS, IBTR
53  2017 Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic Breast Cancer. CPM, QALYs, UM
54  2017 Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis. DCIS, IBC, LC, NMA, ORs, RT, SUCRA
55  2017 Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. CIs, ER, PR, RRs
56  2017 Mammographic breast density is associated with the development of contralateral breast cancer. BC, BD
57  2017 Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. OR, PHBC, UVA/MVA
58  2016 Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. BCT, BMI, CI, DM, HR, LRR
59  2016 Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. BMI, CI, ER, RR, WECARE
60  2016 Breast cancer treatment in mutation carriers: surgical treatment. BCT, IBR, NAC, NSM
61  2016 Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. ---
62  2016 Contralateral prophylactic mastectomy: current perspectives. CPM
63  2016 Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. BP, CI, HR
64  2016 Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. ---
65  2016 Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry. UBC
66  2016 Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). CPM, ER, QALYs
67  2016 Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour. BC, CPM, TPB
68  2016 Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. AIB1, ER
69  2016 Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. CIs, RRs
70  2016 Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study. pts, TNBC, UBC
71  2015 'Taking control of cancer': understanding women's choice for mastectomy. BCT, CPM, ESBC
72  2015 Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. CPM, ER
73  2015 Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. ---
74  2015 Contralateral breast cancer: a clinico-pathological study of second primaries in opposite breasts after treatment of breast malignancy. ---
75  2015 Exome sequencing of contralateral breast cancer identifies metastatic disease. ---
76  2015 Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. DR, HR, LRR, TEAM
77  2015 Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer. CI, CPM, IQR, RR, TSSM
78  2015 Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study. CPM
79  2015 Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. ---
80  2015 Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer. ---
81  2015 Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. CI, ER, FTP, RR, WECARE
82  2015 Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer. DSS, OS, UBC
83  2015 Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. CIs, RRs
84  2015 Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer. ACE
85  2014 Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. BCM, CIs, CPM, MCBC, OS, RDs, RRs, UBC
86  2014 Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. CPM, ICER, QALY, UM
87  2014 Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. ---
88  2014 Factors and outcomes associated with surgical treatment options of contralateral breast cancer. SEER
89  2014 Improved long-term survival with contralateral prophylactic mastectomy among young women. CPM, DFS, OS
90  2014 Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. ---
91  2014 Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon? CPM
92  2014 Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. OS
93  2014 Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. BCS, CI, DCIS, HR, LRR, MRI, RT
94  2014 Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. BC, CPM, DCIS, OC
95  2014 Recent BRCAPRO upgrades significantly improve calibration. CGN
96  2014 Risk of contralateral breast cancer after tamoxifen use among Danish women. CI, DBCG, HRs
97  2014 Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. FBC, HR, SIRs
98  2014 Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. IBR
99  2014 Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. CPM, DSS, OS, SM
100  2014 Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. CPM, ER, LE